Development of an innovative nanopolymer-lncRNA-SRHC complex as therapeutic modalities for targeted hepatocellular carcinoma therapy

Bibliographic Information
Authors: Elkramani N.; Elzallat M.; Mohammed D.M.; AbdelLatif A.; Aboushousha T.; El-Ahwany E.
Journal: Scientific Reports
Publisher: Nature Research
Publication Date: 9 May 2026
Volume / Issue: Volume 16 / Issue 1
Article No.: 14695
ISSN: 20452322
DOI: 10.1038/s41598-026-51340-1
Scopus: View on Scopus
PubMed: 42106389
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Elkramani N., Biotechnology Program and Biology Department, School of Science and Engineering, American University in Cairo, Cairo, Egypt; Elzallat M., Laboratory Department, Mubarak Al-Kabeer Hospital, Ministry of Health, Jabriya, Kuwait; Mohammed D.M., Nutrition and Food Science Department, National Research Centre, Dokki, Giza, 12622, Egypt; AbdelLatif A., Biotechnology Program and Biology Department, School of Science and Engineering, American University in Cairo, Cairo, Egypt; Aboushousha T., Pathology Department, Theodor Bilharz Research Institute, Giza, Egypt; El-Ahwany E., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Hepatocellular carcinoma (HCC) is a global crisis. Long noncoding RNAs (lncRNAs) are anticipated to be significant players in the pathogenesis of HCC in a multitude of ways, including tumor progression, proliferation, invasion, metastasis, and recurrence. To limit the progression of hepatocarcinogenesis, we employ a new treatment regimen that delivers lncRNA SRHC via polymer nanoparticles. A total of 100 mice were divided into five different groups. The initial group served as a control and received saline injections. On the other hand, the pathological-control group received weekly N-Nitrosodiethylamine (DEN) injections for 16 weeks. The remaining three groups received injections of polymer nanoparticles (NPs), long noncoding RNA SRHC alone, or conjugated NPs, respectively, once a week for four weeks, starting in the 12th week after DEN injection. After 16 weeks, the animals were euthanized, and liver specimens and blood samples were collected for biochemical, molecular, and pathological evaluations. Using nanoconjugates containing the lncRNA SRHC significantly improved tumor-associated biomarkers and histopathology compared with the pathological-control group. Furthermore, the expression of SENP1 and PCNA was downregulated. In conclusion, SRHC-conjugated nanoparticles are more likely to be considered a cutting-edge HCC treatment protocol. © The Author(s) 2026.
Keywords
Biocompatibility; Hepatocellular carcinoma (HCC); lncRNA-SRHC; Macromolecular strategy; Nanopolymer conjugates; Targeted drug delivery; Animals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Mice; Nanoparticles; Polymers; RNA, Long Noncoding; long untranslated RNA; nanoparticle; polymer; animal; chemistry; drug therapy; genetics; human; liver cell carcinoma; liver tumor; mouse; pathology; therapy
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
